¼¼°èÀÇ ±¸¼øÆ÷Áø Ä¡·á ½ÃÀå
Cold Sore Treatment
»óǰÄÚµå : 1732008
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 469 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,026,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,080,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ±¸¼øÆ÷Áø Ä¡·á ½ÃÀåÀº 2030³â±îÁö 13¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 9¾ï 9,300¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ±¸¼øÆ÷Áø Ä¡·á ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 4.8%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 13¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ±¹¼Ò Ä¡·áÁ¦´Â CAGR 3.8%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 7¾ï 3,510¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °æ±¸ Ä¡·á ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 6.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2¾ï 7,050¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ±¸¼øÆ÷Áø Ä¡·á ½ÃÀåÀº 2024³â¿¡ 2¾ï 7,050¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀÌ 7.4%·Î, 2030³â±îÁö 2¾ï 5,660¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.4%¿Í 4.7%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ±¸¼øÆ÷Áø Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÇǺΰú¿Í Ç×¹ÙÀÌ·¯½º Ä¡·á¿¡¼­ ±¸¼øÆ÷Áø Ä¡·á°¡ Áö¼ÓÀûÀ¸·Î ÁÖ¸ñ¹Þ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

ÁÖ·Î Ç츣Æä½º ¹ÙÀÌ·¯½º 1Çü(HSV-1)¿¡ ÀÇÇØ ¹ß»ýÇÏ´Â ±¸¼øÆ÷ÁøÀº ¿©ÀüÈ÷ Àü ¼¼°è¿¡¼­ °¡Àå ÈçÇÏ°í ¹Ýº¹ÀûÀ¸·Î Àç¹ßÇÏ´Â ¹ÙÀÌ·¯½º °¨¿° Áúȯ Áß ÇϳªÀÔ´Ï´Ù. Àα¸ÀÇ »ó´ç¼ö°¡ ¾Î°í ÀÖ´Â ÀÌ º´º¯Àº ºÒÆíÇÔ°ú ½É¹ÌÀû ¹®Á¦¸¦ ¾ß±âÇÒ »Ó¸¸ ¾Æ´Ï¶ó °¨¿°ÀÇ À§Çèµµ ÀÖ½À´Ï´Ù. ½ºÆ®·¹½º, Áúº´, ÇÞºû ³ëÃ⠵ ÀÇÇØ À¯¹ßµÇ´Â Àç¹ß¼º ÁúȯÀ̱⠶§¹®¿¡ Áõ»óÀ» °ü¸®Çϰí, ¹ßº´ ±â°£À» ´ÜÃàÇϸç, Àç¹ßÀ» ¾ïÁ¦ÇÏ´Â È¿°úÀûÀÎ Ä¡·á¹ýÀÌ Àå±âÀûÀ¸·Î ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù.

±¸¼øÆ÷ÁøÀº »ý¸íÀ» À§ÇùÇÏ´Â ÁúȯÀº ¾Æ´ÏÁö¸¸, ƯÈ÷ ´«¿¡ º¸À̰ųª ÅëÁõÀ» µ¿¹ÝÇÏ´Â °æ¿ì ȯÀÚÀÇ »îÀÇ Áú°ú »çȸÀû ±³·ù¿¡ Å« ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ÀϹÝÀǾàǰ(OTC) ¹× 󹿾àÀ¸·Î Ä¡·á°¡ °¡´ÉÇѵ¥´Ù Á¶±â °³ÀÔ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Ä¡·á¸¦ ¿øÇϴ ȯÀÚÃþÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¼ÒºñÀÚÀÇ °Ç°­ µ¿ÇâÀÌ ¼¿ÇÁ Äɾ ÁßÁ¡À» µÎ´Â °¡¿îµ¥, È¥¶õÀ» ÃÖ¼ÒÈ­Çϰí Ä¡À¯¸¦ °¡¼ÓÈ­Çϸç, Áï°¢ÀûÀÎ È¿°ú¿Í »ç¿ë ÆíÀǼºÀ» °®Ãá Ç×¹ÙÀÌ·¯½ºÁ¦·ÎÀÇ ÀüȯÀº ºÐ¸íÇÕ´Ï´Ù.

È¿´É°ú ÆíÀǼºÀ» Çâ»ó½Ã۱â À§ÇØ Ä¡·á Ŭ·¡½º¿Í Åõ¿© ÇüÅ´ ¾î¶»°Ô ÁøÈ­Çϰí Àִ°¡?

Acyclovir, Baraciclovir, Famciclovir¿Í °°Àº Ç×¹ÙÀÌ·¯½ºÁ¦´Â ¿Ü¿ëÁ¦¿Í °æ±¸Á¦·Î »ç¿ë °¡´ÉÇϸç, ¿©ÀüÈ÷ 1Â÷ ¼±Åà ¾à¹°·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÁßÁõ ¶Ç´Â ºó¹øÇÑ °¨¿°ÀÇ °æ¿ì Àü½Å Ä¡·áÁ¦°¡ ¹Ù¶÷Á÷ÇÏÁö¸¸, ±¹¼Ò¿ë Å©¸²À̳ª Á©Àº ±¹¼Ò Áõ»óÀ» ºü¸£°Ô ¿ÏÈ­ÇÏ°í »ç¿ëÀÌ °£ÆíÇÕ´Ï´Ù. ÃÖ±Ù Çõ½ÅÀûÀÎ Ä¡·á¹ýÀ¸·Î´Â ¸®Æ÷Á» Àü´Þ ½Ã½ºÅÛ, ÇÏÀ̵å·ÎÄÝ·ÎÀÌµå ÆÐÄ¡, »ýü Á¢Âø Çʸ§ µîÀÌ ÀÖÀ¸¸ç, ¾à¹°ÀÇ À¯Áö·Â°ú À庮 º¸È£¸¦ Çâ»ó½ÃÄÑ º´º¯ ºÎÀ§¿¡¼­ÀÇ Ä¡·á È¿°ú¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù.

±¸¼øÆ÷Áø¿¡ ƯȭµÈ ¹Ì¼¼Àü·ù Àåºñ³ª ±¤Ä¡·á±â µîÀÇ »õ·Î¿î Àü´Þ Çüŵµ ¾à¸® ÀÛ¿ëÀ» ÇÏ´Â ¾à¹°À» »ç¿ëÇÏÁö ¾Ê°íµµ ¹ÙÀÌ·¯½º º¹Á¦¸¦ ¾ïÁ¦ÇÏ°í º´º¯ÀÇ ¼Ò½ÇÀ» ¾Õ´ç±æ ¼ö ÀÖ´Ù´Â Á¡¿¡¼­ ¼ÒºñÀÚÀÇ °ü½ÉÀ» ²ø°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¸Á¶ ±â¼úµéÀº ¼ÒºñÀÚ¿¡°Ô Á÷Á¢ ÆÇ¸ÅµÇ´Â °æ¿ì°¡ ¸¹À¸¸ç, ¾à¹°À» »ç¿ëÇÏÁö ¾Ê´Â Ä¡·á³ª º´¿ë Ä¡·á¸¦ ¿øÇÏ´Â ¼ÒºñÀڵ鿡°Ô ¾îÇÊÇϰí ÀÖ½À´Ï´Ù. ¿ø°Ý ÇǺΰú ¹× e-¾à±¹ Ç÷§ÆûÀÇ ¼ºÀåÀº ó¹æ Ç×¹ÙÀÌ·¯½ºÁ¦¿¡ ´ëÇÑ ½Å¼ÓÇÑ Á¢±ÙÀ» ´õ¿í ÃËÁøÇϰí, °³º°È­µÈ ¹ßº´ °ü¸® Àü·«ÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå º¸±ÞÀ» ÁÖµµÇÏ´Â ¼ÒºñÀÚ ºÎ¹®°ú ÇコÄɾî ä³ÎÀº?

ÀþÀº Ãþ°ú ÁßÀå³âÃþ, ƯÈ÷ »çȸÀû Âü¿©µµ°¡ ³ô°í ¿Ü¸ð¸¦ Áß½ÃÇÏ´Â ¶óÀÌÇÁ½ºÅ¸ÀÏÀ» °¡Áø °èÃþÀº °¡Àå Àû±ØÀûÀÎ ¼ÒºñÀÚÀÔ´Ï´Ù. ÀÌ °èÃþÀº ¹ÌÀû, »çȸÀû È¥¶õÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇØ Á¶±â Áõ»ó Á¶ÀýÀ» ¿øÇϸç, Á¾Á¾ Áï°¢ÀûÀÎ È¿°ú°¡ ÀÖ´Â OTC Á¦Ç°À» ¼±È£ÇÕ´Ï´Ù. ¶ÇÇÑ Ã³À½À¸·Î ÀÌ ÁúȯÀ» ¾Î°í ÀÖ´Â »ç¶÷µéÀÇ ÀνÄÀÌ ³ô¾ÆÁö°í, ÁÖ·ù ¹Ìµð¾î¿¡¼­ ±¸¼øÆ÷Áø¿¡ ´ëÇÑ À̾߱Ⱑ ´Ù·ç¾îÁö¸é¼­ Æí°ßÀÌ »ç¶óÁö°í, ´õ ³ÐÀº ¿¬·ÉÃþ¿¡¼­ Ä¡·á ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

OTC Ä¡·áÁ¦ÀÇ ±¤¹üÀ§ÇÑ °¡¿ë¼º°ú ¾à»ç ÃßõÀ¸·Î ÀÎÇØ ¼Ò¸ÅÁ¡ ¹× ¿Â¶óÀÎ ¾à±¹ÀÌ ÁÖ¿ä ÆÇ¸Å Ã¤³ÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÇǺΰú Ŭ¸®´Ð°ú 1Â÷ Áø·á¼Ò¿¡¼­´Â ƯÈ÷ Àü½Å Ç×¹ÙÀÌ·¯½ºÁ¦³ª °¨º° Áø´ÜÀÌ ÇÊ¿äÇÑ ¸¸¼º ¶Ç´Â º¹ÀâÇÑ È¯ÀÚµéÀ» °ü¸®Çϰí ÀÖÀ¸¸ç, E-CommerceÀÇ ¼ºÀå°ú ¼ÒºñÀÚ Á÷Á¢ ¸¶ÄÉÆÃÀ¸·Î ÀÎÇØ Á¦¾à ºê·£µåµéÀº ÆíÀǼºÀ» °­Á¶ÇÑ ±¸µ¶ ¸ðµ¨, ¹øµé Á¦Ç°, ¾Öµå¹öŸÀÌ¡, ºê·£µå ·Î¿­Æ¼, ±×¸®°í ¹øµé Á¦Ç°, ºê·£µå Ãæ¼ºµµ ¹× ºê·£µå Ãæ¼ºµµ¸¦ ³ôÀ̱â À§ÇÑ ±³À° ÄÁÅÙÃ÷·Î ƯÁ¤ ¼ÒºñÀÚÃþÀ» Ÿ°ÙÆÃÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

±ÔÁ¦, ºê·£µå, °¡°Ý Àü·«Àº ¾î¶»°Ô °æÀï Æ÷Áö¼Å´×À» Çü¼ºÇϰí Àִ°¡?

°¨±â Ä¡·áÁ¦ ½ÃÀåÀº °æÀïÀÌ Ä¡¿­Çϸç, ¼ö¸¹Àº Á¦³×¸¯°ú ºê·£µå Á¦Á¦°¡ È¿´É, È¿°ú, ½Å¼Ó¼º, »ç¿ëÀÚ °æÇèÀ¸·Î °æÀïÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ °æ·Î´Â Áö¿ª¿¡ µû¶ó ´Ù¸£¸ç, ó¹æÀüÀÌ ÇÊ¿äÇÑ Ç×¹ÙÀÌ·¯½º Ä¡·áÁ¦°¡ Àִ°¡ Çϸé, OTC ÀǾàǰµµ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦ ¼¼ºÐÈ­´Â °¡°Ý Ã¥Á¤, ¸¶ÄÉÆÃ À¯¿¬¼º, ½ÃÀå Á¢±Ù¼º¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. °¢ ºê·£µå´Â »õ·Î¿î Àü´Þ Çü½Ä, º¸½ÀÁ¦³ª ¸¶ÃëÁ¦ µîÀÇ ºÎ°¡°¡Ä¡ ¼ººÐ, ½Å·Ú¼ºÀ» ³ôÀ̱â À§ÇÑ ÀÓ»óÀÇ Ãßõ µîÀ» ÅëÇØ Â÷º°È­¸¦ ²ÒÇϰí ÀÖ½À´Ï´Ù.

ƯÈ÷ OTC ºÐ¾ß¿¡¼­´Â °¡°Ý ¹Î°¨µµ°¡ µÎµå·¯Áö°í, ¼ÒºñÀÚÀÇ ¼±ÅÃÀº ÀÎÁöµÈ È¿°ú, ¼Óµµ, ¿ÏÈ­ Áö¼Ó½Ã°£¿¡ ¿µÇâÀ» ¹Þ½À´Ï´Ù. ±â¾÷Àº ¸ÅÀå ¹èÄ¡, ÀÎÇ÷ç¾ð¼­ ¸¶ÄÉÆÃ, µðÁöÅÐ °Ç°­ Ç÷§ÆûÀ» °áÇÕÇÑ ¸ÖƼ ä³Î ºê·£µù Àü·«À» Ȱ¿ëÇÏ¿© ¼ÒºñÀÚÀÇ ½Å·Ú¸¦ ½×°í ¹ßº´½Ã Ãæµ¿±¸¸Å¸¦ À¯µµÇϰí ÀÖ½À´Ï´Ù. ±¸¼øÆ÷Áø Ä¡·á°¡ ¼¿ÇÁ ÄÉ¾î ¿µ¿ªÀ¸·Î ´õ¿í À̵¿ÇÔ¿¡ µû¶ó ÆÐŰÁö µðÀÚÀÎ, »ç¿ë ÆíÀǼº, »ç¿ëÀÚ ±³À°ÀÌ ºê·£µå ¼±È£µµ ¹× Ä¡·á Áö¼Ó¼º¿¡ Á¡Á¡ ´õ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

±¸¼øÆ÷Áø Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

½ÃÀå ¼ºÀåÀº HSV-1ÀÇ ³ôÀº ¼¼°è À¯º´·ü, ¼ÒºñÀÚ ÀÎ½Ä Áõ°¡, º´º¯ÀÇ Áö¼Ó ±â°£°ú °¡½Ã¼ºÀ» ´ÜÃàÇÏ´Â Áï°¢ÀûÀ̰í Á¢±ÙÇϱ⠽¬¿î Ä¡·áÁ¦¿¡ ´ëÇÑ °­ÇÑ ¼±È£¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÀÚ°¡ °ü¸® ÀÇ·á·ÎÀÇ Àüȯ°ú ¿Â¶óÀÎ °Ç°­ Á¦Ç° ±¸¸ÅÀÇ ÆíÀǼº Áõ°¡´Â ±âÁ¸ Áö¿ª°ú ½ÅÈï Áö¿ª ¸ðµÎ¿¡¼­ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¾à¹° Á¦Çü, Àü´Þ ½Ã½ºÅÛ, º¸Á¶±â±¸ÀÇ Çõ½ÅÀº ƯÈ÷ °¨±â¸¦ ÀÚÁÖ ¾Î°í ÀÖ´Â ¼ÒºñÀڵ鿡°Ô º¸´Ù ¸ÂÃãÈ­µÈ Ä¡·á¸¦ °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.

±¸¼øÆ÷Áø¿¡ ´ëÇÑ ³«ÀÎÀÌ ÁÙ¾îµé°í Á¦Ç° Çõ½ÅÀÌ °¡¼ÓÈ­µÊ¿¡ µû¶ó È¿°ú, ½ÅÁßÇÔ, Æí¸®ÇÔÀÇ ±ÕÇüÀ» ¸ÂÃâ ¼ö ÀÖ´Â ºê·£µå°¡ Áö¼ÓÀûÀÎ ½ÃÀå Á¡À¯À²À» È®º¸ÇÏ´Â µ¥ °¡Àå À¯¸®ÇÑ À§Ä¡¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. Ä¡·á ÇÁ·Î¹ÙÀÌ´õ°¡ µðÁöÅÐ °Ç°­ ÅøÀ» ´õ¿í ÅëÇÕÇϰí, Ç¥Àû Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °³¼±Çϰí, ÁøÈ­ÇÏ´Â ¼ÒºñÀÚÀÇ ±â´ë¿¡ ºÎÀÀÇÒ ¼ö ÀÖ´ÂÁö ¿©ºÎ°¡ ½ÃÀåÀÇ ´ÙÀ½ ´Ü°è¸¦ Çü¼ºÇÏ°Ô µÉ °ÍÀÔ´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(±¹¼Ò Ä¡·áÁ¦, °æ±¸ Ä¡·áÁ¦, ±¤Ä¡·áÁ¦); ±¸¼øÆ÷Áø À¯Çü(ÀÏÂ÷ °¨¿°, Àç¹ß¼º °¨¿°); ¿¬·ÉÃþ(¼Ò¾Æ, »çÃá±â, ¼ºÀÎ); ÆÇ¸Åä³Î(º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ ¾à±¹)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÃÑ 43°Ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÔ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

¹«·á ¾÷µ¥ÀÌÆ® °¢±¹ÀÇ ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ, 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» °í°´´Ôµé²² Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ <gt; Áß±¹ <gt; ¸ß½ÃÄÚ <gt; ij³ª´Ù <gt;EU <gt; ÀϺ» <gt; Àεµ <gt; ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Cold Sore Treatment Market to Reach US$1.3 Billion by 2030

The global market for Cold Sore Treatment estimated at US$993.0 Million in the year 2024, is expected to reach US$1.3 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Topical Treatments, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$735.1 Million by the end of the analysis period. Growth in the Oral Treatments segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$270.5 Million While China is Forecast to Grow at 7.4% CAGR

The Cold Sore Treatment market in the U.S. is estimated at US$270.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$256.6 Million by the year 2030 trailing a CAGR of 7.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Global Cold Sore Treatment Market - Key Trends & Drivers Summarized

Why Is Cold Sore Treatment a Persistent Focus in Dermatology and Antiviral Therapy?

Cold sores, caused primarily by herpes simplex virus type 1 (HSV-1), remain among the most common and recurring viral infections globally. Affecting a significant portion of the population, these lesions not only cause discomfort and aesthetic concern but also pose transmission risks. The recurrent nature of outbreaks-triggered by stress, illness, or sun exposure-has sustained long-term demand for effective treatment options that can manage symptoms, shorten episode duration, and reduce recurrence.

Despite being a non-life-threatening condition, cold sores significantly impact patient quality of life and social interactions, especially in visible or painful cases. The availability of over-the-counter (OTC) and prescription therapies, along with growing awareness of early intervention, has expanded the treatment-seeking population. As consumer health trends emphasize self-care, there is a clear shift toward fast-acting, user-friendly antiviral solutions that minimize disruption and speed healing.

How Are Therapeutic Classes and Delivery Formats Evolving to Improve Efficacy and Convenience?

Antiviral agents such as acyclovir, valacyclovir, and famciclovir continue to serve as first-line therapies, available in both topical and oral formulations. While systemic drugs are preferred for severe or frequent outbreaks, topical creams and gels offer rapid localized relief and ease of use. Recent innovations include liposomal delivery systems, hydrocolloid patches, and bioadhesive films that improve drug retention and barrier protection-enhancing treatment effectiveness at the lesion site.

Emerging delivery formats such as cold sore-specific microcurrent devices and light therapy tools are also gaining consumer interest for their potential to reduce viral replication and speed lesion resolution without pharmacological agents. These adjunctive technologies, often marketed directly to consumers, appeal to individuals seeking drug-free or combination treatments. The growth of teledermatology and e-pharmacy platforms is further supporting fast access to prescription antivirals and fueling adoption of personalized outbreak management strategies.

Which Consumer Segments and Healthcare Channels Are Driving Market Penetration?

Young adults and middle-aged populations-particularly those with high social engagement and appearance-conscious lifestyles-represent the most proactive cold sore treatment consumers. This demographic seeks early symptom control to minimize aesthetic and social disruption, often favoring rapid-onset OTC products. Increasing awareness among first-time sufferers and growing acceptance of cold sore discussions in mainstream media are also reducing stigma and expanding treatment demand among broader age groups.

Pharmacies, both retail and online, serve as the primary distribution channels, given the wide availability of OTC treatments and pharmacist-led recommendations. Dermatology clinics and primary care practices continue to manage chronic or complicated cases, especially where systemic antivirals or differential diagnosis are warranted. E-commerce growth and direct-to-consumer marketing are enabling pharmaceutical brands to target specific consumer segments with convenience-based subscription models, bundled offerings, and educational content designed to improve adherence and brand loyalty.

How Are Regulatory, Branding, and Pricing Strategies Shaping Competitive Positioning?

The cold sore treatment market is highly competitive, with numerous generic formulations and brand-name options competing on efficacy claims, speed of action, and user experience. Regulatory pathways vary across regions, with some antiviral treatments requiring prescriptions and others available OTC. This regulatory fragmentation influences pricing, marketing flexibility, and access across markets. Brands are differentiating through novel delivery formats, value-added ingredients like moisturizers or anesthetics, and clinician endorsements to reinforce credibility.

Pricing sensitivity is notable, especially in OTC segments, where consumer choices are influenced by perceived effectiveness, speed, and duration of relief. Companies are leveraging multi-channel branding strategies-combining in-store placement, influencer marketing, and digital health platforms-to build consumer trust and trigger impulse purchases during outbreak onset. As cold sore treatments shift further into self-care territory, packaging design, ease of application, and user education are playing increasingly important roles in brand preference and treatment adherence.

What Are the Factors Driving Growth in the Cold Sore Treatment Market?

Market growth is being driven by high global prevalence of HSV-1, increased consumer awareness, and a strong preference for fast-acting, accessible therapies that reduce lesion duration and visibility. The shift toward self-managed care, combined with rising comfort in purchasing health products online, is expanding demand across both established and emerging regions. Innovation in drug formulations, delivery systems, and adjunctive devices is enabling more tailored treatment experiences, especially for consumers managing frequent outbreaks.

As the stigma around cold sores continues to decline and product innovation accelerates, brands that can balance efficacy, discretion, and convenience will be best positioned for sustained market share. Whether treatment providers can further integrate digital health tools, improve access to targeted therapies, and align with evolving consumer expectations will shape the market’s next phase-where cold sore management becomes not just about symptom relief, but about proactive, confident personal care.

SCOPE OF STUDY:

The report analyzes the Cold Sore Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Topical Treatments, Oral Treatments, Light-based Treatments); Cold Sore Type (Primary Outbreaks, Recurrent Outbreaks); Age Group (Children, Adolescents, Adults); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â